https://www.selleckchem.com/pr....oducts/pexidartinib-
De novo genic and copy number variants are enriched in patients with congenital heart disease, particularly those with extra-cardiac anomalies. The impact of de novo damaging variants on outcomes following cardiac repair is unknown. We studied 2517 patients with congenital heart disease who had undergone whole-exome sequencing as part of the CHD GENES study (Congenital Heart Disease Genetic Network). Two hundred ninety-four patients (11.7%) had clinically significant de novo variants. Patients with de novo damaging variants
Like
Comment
Share
